Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: August 2013

Section 5 - Other issues

References

1. Martinez-MartinP.An introduction to the concept of “quality of life in Parkinson's disease”. J Neurol 1998; 245 (Suppl 1): S2–5.
2. WitjasT, KaphanE, AzulayJP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.
3. Martinez-MartinP, SchapiraAH, StocchiF, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting: study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007; 22: 1623–9.
4. LeeMA, PrenticeWM, HildrethAJ, WalkerRW.Measuring symptom load in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 284–9.
5. GallagherDA, LeesAJ, SchragA.What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?Mov Disord 2010; 25: 2493–500.
6. Martinez-MartinP, Rodriguez-BlazquezC, KurtisMM, ChaudhuriKR, on behalf of the NMSS Validation Group. The impact of non motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399–406.
7. Martinez-MartinP, Rodriguez-BlazquezC, AbeK, et al. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009; 73: 1584–91.
8. ForsaaEB, LarsenJP, Wentzel-LarsenT, HerlofsonK, AlvesG.Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008; 23: 1420–7.
9. BaroneP, AntoniniA, ColosimoC, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641–9.
10. SohSE, MorrisME, McGinleyJL.Determinants of health-related quality of life in Parkinson's disease: A systematic review. Parkinsonism Relat Disord 2011; 17: 1–9.
11. Carod-ArtalFJ, ZiomkowskiS, MesquitaHM, Martínez-MartinP.Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 102–8.
12. MuslimovicD, PostB, SpeelmanJD, SchmandB, de HaanRJ; CARPA Study Group. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008; 70: 2241–7.
13. BoddenME, MollenhauerB, TrenkwalderC, et al. Affective and cognitive Theory of Mind in patients with Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 466–70.
14. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17: 60–7.
15. RichardIH, KurlanR.A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997; 49: 1168–70.
16. MacGillivrayS, ArrollB, HatcherS, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326: 1014.
17. AntoniniA, TeseiS, ZecchinelliA, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006; 21: 1119–22.
18. BaroneP, PoeweW, AlbrechtS, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–80.
19. MenzaM, DeFronzo DobkinR, MarinH, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 2009; 24: 1325–32.
20. McKinlayA, GraceRC, Dalrymple-AlfordJC, et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord 2008; 14: 37–42.
21. PontoneGM, WilliamsJR, AndersonKE, et al. Anxiety and self-perceived health status in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 249–54.
22. AarslandD, MarshL, SchragA.Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; 24: 2175–86.
23. Gomez-EstebanJC, TijeroB, SommeJ, et al. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. J Neurol 2011; 258: 494–9.
24. Martinez-MartinP, CatalanMJ, Benito-LeonJ, et al. Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS). Qual Life Res 2006; 15: 597–606.
25. KarlsenK, LarsenJP, TandbergE, JørgensenK.Fatigue in patients with Parkinson's disease. Mov Disord 1999; 14: 237–241.
26. LarsenJP, KarlsenK, TandbergE.Clinical problems in non-fluctuating patients with Parkinson's disease: a community based study. Mov Disord 2000; 15: 826–9.
27. HerlofsonK, LarsenJP.The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003; 107: 1–6.
28. RahmanS, GriffinHJ, QuinnNP, JahanshahiM.Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008; 23: 1428–34.
29. Sanchez-RamosJR, OrtollR, PaulsonGW.Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265–8.
30. InzelbergR, KipervasserS, KorczynAD.Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 533–5.
31. FénelonG, MahieuxF, HulonR, ZiéglerM.Hallucinations in Parkinson's disease: prevalence, phenomenology, and risk factors. Brain 2000; 123: 733–45.
32. SiriC, CiliaR, De GaspariD, VillaF, et al. Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. Neurol Sci 2010; 31: 35–40.
33. WilliamsDR, LeesAJ.Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–10.
34. PapapetropoulosS, ArgyriouAA, EllulJ.Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 2005; 252: 1223–8.
35. PacchettiC, ManniR, ZangagliaR, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005; 20: 1439–48.
36. MarshL, WilliamsJR, RoccoM, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004; 63: 293–300.
37. SchneiderF, AlthausA, BackesV, DodelR.Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci 2008; 258 (Suppl 5): 55–9.
38. LawrenceAJ, BlackwellAD, BarkerRA, et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord 2007; 22: 2339–45.
39. EmreM, AarslandD, BrownR, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689–707.
40. AarslandD, AndersenK, LarsenJP, LolkA, Kragh-SørensenP.Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.
41. AarslandD, AndersenK, LarsenJP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56: 730–6.
42. HallidayG, HelyM, ReidW, MorrisJ.The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409–15.
43. KarlsenKH, LarsenJP, TandbergE, MaelandJG.Quality of life measurements in patients with Parkinson's disease: a community-based study. Eur J Neurol 1998; 5: 443–50.
44. SchragA, JahanshahiM, QuinnN.What contributes to quality of life in patients with Parkinson's disease?J Neurol Neurosurg Psychiatry 2000; 69: 308–12.
45. KlepacN, TrkuljaV, ReljaM, BabićT.Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol 2008; 15: 128–33.
46. SchiehserDM, HanSD, LessigS, et al. Predictors of health status in nondepressed and nondemented individuals with Parkinson's disease. Arch Clin Neuropsychol 2009; 24: 699–709.
47. VisserM, VerbaanD, van RoodenS, et al. A longitudinal evaluation of health-related quality of life of patients with Parkinson's disease. Value Health 2009; 12: 392–6.

References

1. FahnS.Secondary parkinsonism. In GoldensohnES, ApelSH, eds., Scientific Approaches to Clinical Neurology. Philadelphia, PA: Lea & Febiger; 1977. pp. 1159–89.
2. PappMI, KahnJE, LantosPL.Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94: 79–100.
3. BowerJH, MaraganoreDM, McDonnellSK, RoccaWA.Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota. Neurology 1997; 49: 1284–8.
4. GilmanS, LowP, QuinnN, et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 1998; 8: 359–62.
5. GilmanS, WenningGK, LowPA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–6.
6. KaoAW, RacineCA, QuitaniaLC, et al. Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord 2009; 23: 365–70.
7. BakTH, CrawfordLM, HearnVC, MathuranathPS, HodgesJR.Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005; 11: 268–73.
8. FolsteinMF, FolsteinSE, McHughPR.“Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.
9. BürkK, DaumI, RübU.Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 2006; 21: 772–6.
10. FetoniV, SoliveriP, MonzaD, TestaD, GirottiF.Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999; 66: 541–4.
11. ChangCC, ChangYY, ChangWN, et al. Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol 2009; 16: 1144–50.
12. BalasM, BalashY, GiladiN, GurevichT.Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. J Neural Transm 2010; 117: 369–75.
13. KawaiY, SuenagaM, TakedaA, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008; 70: 1390–6.
14. KitayamaM, Wada-IsoeK, IrizawaY, NakashimaK.Assessment of dementia in patients with multiple system atrophy. Eur J Neurol 2009; 16: 589–94.
15. MattisS.Dementia Rating Scale. Windsor: NFER-Nelson; 1988.
16. MathuranathPS, NestorPJ, BerriosGE, RakowiczW, HodgesJR.A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000; 55: 1613–20.
17. MecoG, GaspariniM, DoricchiF.Attentional functions in multiple system atrophy and Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 60: 393–8.
18. BrownRG, LacomblezL, Landwehrmeyer, BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133: 2382–93.
19. DuboisB, SlachevskyA, LitvanI, PillonB.The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621–6.
20. RobbinsTW, JamesM, OwenAM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994; 57: 79–88.
21. Benrud-LarsonLM, SandroniP, SchragA, LowPA.Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 2005; 20: 951–7.
22. GotoK, UekiA, ShimodeH, et al. Depression in multiple system atrophy: a case report. Psychiatry Clin Neurosci 2000; 54: 507–11.
23. HertingB, Beuthien-BaumannB, PöttrichK, et al. Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes. Mov Disord 2007; 22: 490–7.
24. GilmanS, MaySJ, ShultsCW, et al. The North American Multiple System Atrophy Study Group. J Neural Transm 2005; 112: 1687–94.
25. SantamariaJ, IranzoA.Multiple system atrophy and sleep. Sleep Med Clin 2008; 3: 337–45.
26. Moreno-LópezC, SantamaríaJ, SalameroM, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 2011; 68: 223–30.
27. GamaRL, TávoraDG, BomfimRC, et al. Sleep disturbances and MRI morphometry in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy – a comparative study. Parkinsonism Relat Disord 2010; 16: 275–9.
28. LitvanI, AgidY, CalneD, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDSSPSP international workshop. Neurology 1996; 47: 1–9.
29. O'SullivanSS, MasseyLA, WilliamsDR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131: 1362–72.
30. Donker KaatL, BoonAJ, KamphorstW, et al. Frontal presentation in progressive supranuclear palsy. Neurology 2007; 69: 723–9.
31. AarslandD, LitvanI, SalmonD, et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1215–20.
32. SoliveriP, MonzaD, ParidiD, et al. Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000; 69: 313–8.
33. SoliveriP, PiacentiniS, GirottiF.Limb apraxia and cognitive impairment in progressive supranuclear palsy. Neurocase 2005; 11: 263–7.
34. VanvoorstWA, GreenawayMC, BoeveBF, et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14: 376–8.
35. CotelliM, BorroniB, ManentiR, et al. Action and object naming in frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration. Neuropsychology 2006; 20: 558–65.
36. PaviourDC, PriceSL, JahanshahiM, LeesAJ, FoxNC.Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Mov Disord 2006; 21: 989–96.
37. van der HurkPR, HodgesJR.Episodic and semantic memory in Alzheimer's disease and progressive supranuclear palsy: a comparative study. J Clin Exp Neuropsychol 1995; 17: 459–71.
38. PillonB, DeweerB, MichonA, et al. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology 1994; 44: 1264–70.
39. LitvanI, GrafmanJ, GomezC, ChaseTN.Memory impairment in patients with progressive supranuclear palsy. Arch Neurol 1989; 46: 765–7.
40. BorroniB, AlbericiA, AgostiC, CossedduM, PadovaniA.Pattern of behavioral disturbances in corticobasal degeneration and progressive supranuclear palsy. Int Psychogeriatr 2009; 21: 463–8.
41. CordatoNJ, PantelisC, HallidayGM, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002; 125: 789–800.
42. AarslandD, LitvanI, LarsenJP.Neuropsychiatric symptoms of patients with progressive supranuclear palsy. J Neuropsychiatry Clin Neurosci 2001; 13: 42–9.
43. LitvanI, MegaMS, CummingsJL, FairbanksL.Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47: 1184–9.
44. CooperAD, JosephsKA.Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study. Parkinsonism Relat Disord 2009; 15: 59–61.
45. WenningGK, LitvanI, JankovicJ, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184–9.
46. RinneJO, LeeMS, ThompsonPD, MarsdenCD.Corticobasal degeneration: a clinical study of 36 cases. Brain 1994; 117: 1183–96.
47. LitvanI, AgidY, GoetzC, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 1997; 48: 119–25.
48. MurrayR, NeumannM, FormanMS, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68: 1274–83.
49. GrimesDA, LangAE, BergeronCB.Dementia as the common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53: 1969–74.
50. MorettiR, TorreP, AntonelloRM, CattaruzzaT, CazzatoG.Cognitive impairment in the lateralized phenotype of corticobasal degeneration. Dement Geriatr Cogn Disord 2005; 20: 158–62.
51. GrahamNL, BakT, PattersonK, HodgesJR.Language function and dysfunction in corticobasal degeneration. Neurology 2003; 61: 493–9.
52. KerteszA, Martinez-LageP, DavidsonW, MunozDG.The corticobasal syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000; 55: 1368–75.
53. GedaYE, BoeveBF, NegashS, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007; 19: 77–80.
54. LitvanI, CummingsJL, MegaM.Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65: 717–21.
55. SoliveriP, MonzaD, ParidiD, et al. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999; 53: 502–7.

References

1. GoetzCG, PoeweW, RascolO, SampaioC.Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523–39.
2. AgidY, OlanowC, MizunoY.Levodopa: why the controversy?Lancet 2002; 360: 575.
3. MiyasakiJM, MartinW, SuchowerskyO, WeinerWJ, LangAE.Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58: 11–17.
4. FoxSH, LangAE.Levodopa-related motor complications: phenomenology. Mov Disord 2008; 23 (Suppl 3): S509–14.
5. AhlskogJE, MuenterMD.Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448–58.
6. SchragA, QuinnN.Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297–305.
7. RileyDE, LangAE.The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43: 1459–64.
8. WitjasT, KaphanE, AzulayJP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.
9. StacyM, BowronA, GuttmanM, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20: 726–33.
10. LeesAJ.The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989; 52 (suppl): 29–37.
11. HillenME, SageJI.Motor fluctuations in patients with Parkinson's disease. Neurology 1996; 47: 1180–3.
12. GunalDI, NurichalichiK, TuncerN, BekirogluN, AktanS.The clinical profile of nonmotor fluctuations in Parkinson's disease patients. Can J Neurol Sci 2002; 29: 61–4.
13. BayulkemK, LopezG.Nonmotor fluctuations in Parkinson's disease: clinical spectrum and classification. J Neurol Sci 2010; 289: 89–92.
14. QuinnNP.Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51 (Suppl 2): 25–29.
15. SchragA.Psychiatric aspects of Parkinson's disease–an update. J Neurol 2004; 251: 795–804.
16. ChaudhuriKR, SchapiraAH.Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464–74.
17. OlanowCW, ObesoJA, StocchiF.Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677–87.
18. NuttJG.Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008; 23 (Suppl 3): S580–4.
19. WeintraubD, BurnDJ.Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26: 1022–1031.
20. RichardIH, JustusAW, KurlanR.Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13: 35–41.
21. KulisevskyJ, Pascual-SedanoB, BarbanojM, et al. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a double-blind study. Mov Disord 2007; 22: 62–7.
22. MaricleRA, NuttGJ, ValentineRJ, CarterJH.Dose–response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo controlled study. Neurology 1995; 45: 1757–60.
23. VoonV, FernagutPO, WickensJ, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140–9.
24. AarslandD, UweE, RektorovaI.Cognitive and psychiatric disturbances in Parkinson's disease. Aging Health 2011; 7: 123–42.
25. MarshL, McDonaldWM, CummingsJ, RavinaB.Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148–58.
26. JuddMM, RapaportM, PaulusMB.Subsyndromal symptomatic depression: a new mood disorder?J Clin Psychiatry 1994; 55 (suppl): 18–28.
27. MenzaMA, SageJ, MarshallE, CodyR, DuvoisinR.Mood changes and “on–off” phenomena in Parkinson's disease. Mov Disord 1990; 5: 148–51.
28. GiovannoniG, O'SullivanJD, TurnerK, MansonAJ, LeesAJ.Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–8.
29. LawrenceAD, EvansAH, LeesAJ.Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?Lancet Neurol 2003; 2: 595–604.
30. PontoneGM, WilliamsJR, AndersonKE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24: 1333–8.
31. FunkiewiezA, ArdoinC, CaputoE, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834–9.
32. ThoboisS, ArdouinC, LhomméeE, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111–27.
33. SageJI.Fluctuations of non-motor symptoms. In FactorSA and WeinerWJ, eds., Parkinson's Disease: Diagnosis and Clinical Management. New York, NY: Demos; 2002. pp. 455–63.
34. RaudinoF.Nonmotor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312–15.
35. AarslandD, BrønnickK, Williams-GrayC, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062–9.
36. EmreM, AarslandD, BrownR, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689–707.
37. HelyMA, ReidWG, AdenaMA, HallidayGM, MorrisJG.The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
38. ButerTC, van den HoutA, MatthewsFE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017–1022.
39. AarslandD, BrønnickK, LarsenJP, TysnesOB, AlvesG.Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121–6.
40. MegaMS, CummingsJL.Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6: 358–70.
41. JellingerKA.The pathology of Parkinson's disease. Adv Neurol 2001; 86: 55–72.
42. PillonB, DuboisB, CusimanoG, et al. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?J Neurol Neurosurg Psychiatry 1989; 52: 201–6.
43. RektorovaI, SrovnalovaH, KubikovaR, PrasekJ.Striatal dopamine transporter imaging correlates with depressive symptoms and Tower of London task performance in Parkinson's disease. Mov Disord 2008; 23: 1580–7.
44. KoertsJ, LeendersKL, KoningM, PortmanAT, van BeilenM.Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 2007; 25: 3132–6.
45. KulisevskyJ, García-SánchezC, BerthierML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000; 15: 613–26.
46. CoolsR.Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1–23.
47. NieoullonA.Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002; 67: 53–83.
48. RektorovaI.Effects of dopamine agonists on neuropsychiatric symptoms of Parkinson's disease. Neurodegener Dis 2010; 7: 206–9.
49. BrownRD, MarsdenCD, QuinnN, WykeMA.Alterations in cognitive performance and affect arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47: 454–65.
50. GirottiE, CarellaF, GrassiMP, et al. Motor and cognitive performances of Parkinsonian patients in the “on” and “off” phases of the disease. J Neurol Neurosurg Psychiatry 1986; 49: 657–60.
51. MohrE, FabbriniG, WilliamsJ, et al. Dopamine and memory function in Parkinson's disease. Mov Disord 1989; 4: 113–20.
52. GothamAM, BrownRG, MarsdenCD.“Frontal” cognitive function in patients with Parkinson's disease “on” and “off” levodopa. Brain 1988; 11: 299–321.
53. PoeweW, BergerW, BenkeT, ScheolskyL.High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991; 29: 670–3.
54. DelisD, DirenfeldL, AlexanderMP, KaplanE.Cognitive fluctuations associated with on–off phenomenon in Parkinson's disease. Neurology 1982; 32: 1049–52.
55. Pascual-SedanoB, KulisevskyJ, BarbanojM, et al. Levodopa and executive performance in Parkinson's disease: a randomized study. J Int Neuropsychol Soc 2008; 14: 832–41.
56. StacyM.The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm 2010; 117: 837–46.
57. StacyM, HauserR, OertelW, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006; 29: 312–21.
58. StacyMA, MurphyJM, GreeleyDR, et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008; 14: 205–12.
59. BarešM, RektorováI, JechR, et al. Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?J Neural Transm 2012; 119: 373–80.
60. RektorovaI, RektorI, BaresM, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399–406.
61. LemkeMR, BrechtHM, KoesterJ, ReichmannH.Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006; 248: 266–70.
62. AntoniniA, TolosaE, MizunoY, YamamotoM, PoeweWH.A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929–37.
63. HorstinkM, TolosaE, BonuccelliU, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186–202.
64. HorowskiR, JahnichenS, PertzH.Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 2004; 19: 1523–4.
65. RůzickaE, StreitováH, JechR, et al. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neural Transm 2000; 107: 1297–306.
66. DeweyRB, HuttonJT, LeWittPA, FactorSA.A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385–92.
67. KatzenschlagerR, HughesA, EvansA, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005; 20: 151–7.
68. AntoniniA, IsaiasIU, CanesiM, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145–9.
69. StocchiF, VaccaL, RuggieriS, OlanowCW.Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62: 905–10.
70. BenabidAL, ChabardesS, MitrofanisJ, PollakP.Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009; 8: 67–81.
71. TemelY, BloklandA, SteinbuschHWM, Visser-VandewalleV.The functional role of the subthalamic nucleus in cognitive and limbic circuits. Progr Neurobiol 2005; 76: 393–413.
72. OkunMS, FernandezHH, WuSS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009; 65: 586–95.
73. WittK, PulkowskiU, HerzogJ, et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol 2004; 61: 697–700.
74. TemelY, KesselsA, TanS, et al. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2006; 12: 265–72.
75. VoonV, KubuC, KrackP, HouetoJL, TrösterAI.Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 (Suppl 14): S305–27.
76. FunkiewiezA, ArdouinC, KrackP, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524–30.
77. LimSY, O'SullivanSS, KotschetK, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148–52.
78. HerzogJ, ReiffJ, KrackP, et al. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease. Mov Disord 2003; 18: 1382–4.
79. CzerneckiV, PillonB, HouetoJL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?J Neurol Neurosurg Psychiatry 2005; 76: 775–9.
80. KrackP, BatirA, Van BlercomN, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925–34.
81. StruttAM, SimpsonR, JankovicJ, YorkMK.Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol 2012; 19: 121–7.
82. WitjasT, KaphanE, RégisJ, et al. Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007; 22: 1729–34.
83. PillonB, ArdouinC, DamierP, et al. Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson's disease. Neurology 2000; 55: 411–18.
84. JahanshahiM, ArdouinC, BrownRG, et al. The impact of deep brain stimulation on executive function in Parkinson's disease. Brain 2000; 123: 1142–54.
85. SmedingHM, SpeelmanJD, Koning-HaanstraM, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66: 1830–6.
86. KrackP, PollakP, LimousinP, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998; 121: 451–7.
87. HouetoJL, MesnageV, MalletL, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701–7.

References

1. YoudimMB, BuccafuscoJJ.Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26: 27–35.
2. KimYH, RaneA, LussierS, AndersenJK.Lithium protects against oxidative stress-mediated cell death in α-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. J Neurosci Res 2011; 89: 1666–75.
3. LauterbachEC, FontenelleLF, TeixeiraAL.The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease. Parkinsons Dis 2012; 2012: 753548.
4. GibsonSA, GaoGD, McDonaghK, ShenS.Progress on stem cell research towards the treatment of Parkinson's disease. Stem Cell Res Ther 2012; 3: 11.
5. DenyerR, DouglasMR.Gene therapy for Parkinson's disease. Parkinsons Dis 2012; 2012: 757305.
6. VilasD, Pont-SunyerC, TolosaE.Impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl 1): S80–4.
7. MorelliM, CartaAR, JennerP. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol 2009; (193): 589–615.
8. Pharmaceutical Research and Manufacturers of America. Medicines in Development for Neurological Disorders. Washington, DC: PhRMA; 2008.
9. PrattJ, WinchesterC, DawsonN, MorrisB.Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 2012; 11: 560–79.
10. VisanjiNP, Gomez-RamirezJ, JohnstonTH, et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006; 21: 1879–91.
11. Pharmaceutical Research and Manufacturers of America. Medicines in Development: Mental Illnesses. Washington, DC: PhRMA; 2012.
12. GrayJA, RothBL.The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007; 12: 904–22.
13. McFarlandK, PriceDL, BonhausDW.Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behav Pharmacol 2011; 22: 681–92.
14. MeltzerHY, MillsR, RevellS, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010; 35: 881–92.
15. RichardIH, McDermottMP, KurlanR; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229–36.
16. MenzaM, DobkinRD, MarinH, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886–92.
17. ConnollyKR, ThaseME.Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2012; 17: 105–26.
18. Paez-PeredaM, HauschF, HolsboerF.Corticotropin releasing factor receptor antagonists for major depressive disorder. Expert Opin Investig Drugs 2011; 20: 519–35.
19. ChungC.New perspectives on glutamate receptor antagonists as antidepressants. Arch Pharm Res 2012; 35: 573–7.
20. BrooksBR, ThistedRA, AppelSH, et al.; AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63: 1364–70.
21. PioroEP, BrooksBR, CummingsJ, et al. Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010; 68: 693–702.
22. WangLY, ShoferJB, RohdeK, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009; 17: 744–51.
23. TariotPN, SchneiderLS, CummingsJ, et al.; Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011; 68: 853–61.
24. HolmesC, WilkinsonD, DeanC, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214–19.
25. DevanandDP, PeltonGH, CunqueiroK, SackeimHA, MarderK.A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry 2011; 26: 937–43.
26. FavaM, EvinsAE, DorerDJ, SchoenfeldDA.The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115–27.
27. TamuraRN, HuangX.An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials 2007; 4: 309–17.
28. CummingsJ.Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011; 7: e13–44.
29. KaiserR, HoferA, GrapengiesserA, et al. L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 2003; 60: 1750–5.